Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Inflammatory optic neuropathies].

A Vighetto1, P Krolak-Salmon

  • 1Unité de neuro-ophtalmologie et service de neurologie D Hôpital neurologique Pierre Wertheimer B.P. Lyon-Montchat 69394 Lyon. alain.vighetto@chu-lyon.fr

La Revue Du Praticien
|February 7, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

The pattern of cortical thickness associated with executive dysfunction in MCI and SCC: The MEMENTO cohort.

Revue neurologique·2024
Same author

Prodromal or mild Alzheimer's disease: Influence of neuropsychiatric symptoms and premordid personality on caregivers' burden.

International journal of geriatric psychiatry·2024
Same author

Letter to the editor: Beyond Frailty in Alzheimer's Disease: Should We Move to the Concept of Intrinsic Capacity.

The journal of prevention of Alzheimer's disease·2022
Same author

[Importance of cognitive disorders in internal medicine: Pathophysiology, diagnosis, management. The example of systemic lupus erythematosus].

La Revue de medecine interne·2021
Same author

Determinants of Medical Direct Costs of Care among Patients of a Memory Center.

The journal of prevention of Alzheimer's disease·2021
Same author

[Towards a better recognition of cognitive disorders in internal medicine?]

La Revue de medecine interne·2021
Same journal

[Prolonged fever].

La Revue du praticien·2026
Same journal

[Lower gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[Management of antiplatelet agents and oral anticoagulants in cases of gastrointestinal bleeding].

La Revue du praticien·2026
Same journal

[A history of child abuse intervention in the West].

La Revue du praticien·2026
Same journal

[Agranulocytose médicamenteuse].

La Revue du praticien·2026
Same journal

[Patient education in heart failure].

La Revue du praticien·2026
See all related articles

Diagnosing inflammatory optic neuropathy in young adults with sudden vision loss requires an ophthalmological exam and MRI. While outcomes are favorable, corticosteroids may shorten recovery, and MS risk is assessed via MRI findings.

Area of Science:

  • Ophthalmology
  • Neurology
  • Radiology

Context:

  • Inflammatory optic neuropathy presents as acute, unilateral, and painful vision loss in young adults.
  • A relative afferent pupillary defect is a key diagnostic sign.
  • Ophthalmological examination is crucial for assessing visual acuity and optic nerve appearance.

Purpose:

  • To outline the diagnostic approach for inflammatory optic neuropathy.
  • To discuss the role of Magnetic Resonance Imaging (MRI) in evaluating optic neuritis.
  • To review prognostic indicators and treatment options for optic neuropathy.

Summary:

  • Diagnosis involves clinical presentation, ophthalmological exam, and MRI to rule out compression and assess inflammatory lesions.
  • MRI findings can predict the risk of developing multiple sclerosis (MS).

Related Experiment Videos

  • High-dose parenteral corticosteroids may shorten the duration of optic neuropathy, but long-term benefits of treatments like beta-interferons require further evaluation.

    • Impact:

    • This information aids clinicians in the timely and accurate diagnosis of inflammatory optic neuropathy.
    • Understanding MRI's prognostic value helps in patient counseling regarding MS risk.
    • Clarifies the role of corticosteroids and highlights the need for further research on disease-modifying therapies.